Chapter 3: Pharmacodynamics — Module 6: Applied Clinical Pharmacodynamics — Drug Classes, Receptor Selectivity and Therapeutic Windows
1. A patient with asthma and newly diagnosed hypertension requires antihypertensive therapy. Her cardiologist considers a cardioselective beta-blocker. Which of the following best describes the pharmacodynamic basis for using a cardioselective beta-blocker in a patient with reactive airway disease?
A) No beta-blocker is safe in asthma under any circumstance -- all beta-blockers, regardless of receptor subtype selectivity, must be avoided in any patient with a history of bronchospasm
B) Cardioselective beta-blockers are completely safe in asthma because they bind exclusively to beta1 receptors and have zero affinity for beta2 receptors -- at any dose, airway beta2 receptors are completely spared
C) The safety of beta-blockers in asthma depends not on receptor subtype selectivity but on the intrinsic sympathomimetic activity (ISA) of the drug -- only beta-blockers with ISA are safe in asthma
D) Beta-blockers are safe in asthma only when combined with a beta2 agonist such as salbutamol -- the bronchodilator prevents any beta2 blockade-induced bronchospasm and allows safe use of non-selective agents
E) Cardioselective beta-blockers (metoprolol, bisoprolol) have 10-100 fold higher affinity for beta1 receptors over beta2 receptors at therapeutic plasma concentrations, producing cardiac rate and contractility reduction with substantially less airway beta2 blockade than non-selective agents (propranolol); cardioselectivity is dose-dependent and relative, not absolute -- at high doses, beta2 blockade occurs; cautious use of low-to-moderate doses of cardioselective agents in patients with mild-to-moderate asthma or COPD is generally acceptable with appropriate monitoring, and the cardiovascular benefit (in heart failure, post-MI) may outweigh the respiratory risk in individual patients
ANSWER: E
Rationale:
Cardioselective beta-blockers provide a clinically important pharmacodynamic advantage over non-selective agents in patients with reactive airway disease because their preferential beta1 affinity produces cardiac effects while reducing (but not eliminating) the degree of airway beta2 blockade. Non-selective beta-blockers such as propranolol block beta2 receptors in bronchial smooth muscle with the same affinity as beta1 receptors in the heart -- any degree of beta2 blockade in an asthmatic patient risks precipitating bronchospasm, as these patients depend on endogenous epinephrine-mediated beta2 stimulation to maintain airway tone. Cardioselective agents (metoprolol, bisoprolol, atenolol, nebivolol) have a 10-100 fold preference for beta1 over beta2 -- at low to moderate therapeutic doses, the degree of beta2 blockade is substantially less. Guidelines and evidence support cautious use of cardioselective agents in patients with mild-to-moderate asthma when the cardiovascular indication is strong (heart failure with reduced ejection fraction, post-MI beta-blocker therapy). The caveats are critical: selectivity is dose-dependent (high-dose cardioselective agents will produce significant beta2 blockade); patients with severe asthma or brittle asthma remain at substantial risk; and any patient started on a beta-blocker with airway disease must be monitored for worsening respiratory symptoms.
Option A: Option A is incorrect -- while caution is warranted, non-selective beta-blockers are contraindicated in asthma but cardioselective agents may be used with appropriate caution when benefit outweighs risk.
Option B: Option B is incorrect -- cardioselective agents have relative, not absolute, beta1 selectivity; at high doses they will block beta2 receptors and can precipitate bronchospasm.
Option C: Option C is incorrect -- ISA reduces resting bradycardia and peripheral vasoconstriction but does not specifically protect airways from beta2 blockade in asthma.
Option D: Option D is incorrect -- concurrent salbutamol does not reliably prevent bronchospasm from non-selective beta-blockers and is not the pharmacodynamic solution; receptor selectivity is the relevant consideration.
2. The adverse effect profile of an antipsychotic drug can be predicted directly from its receptor binding affinity table. Using haloperidol as an example, which of the following correctly links receptor binding to clinical adverse effects?
A) Haloperidol's adverse effects are largely unpredictable from its receptor binding profile because adverse effects arise from idiosyncratic metabolic reactions to haloperidol metabolites rather than from on-target pharmacology
B) Haloperidol's adverse effects are entirely explained by its D2 blockade -- all side effects including sedation, orthostatic hypotension, and weight gain are consequences of excessive dopaminergic blockade across all four dopamine pathways
C) Haloperidol's high D2 affinity in the nigrostriatal pathway predicts extrapyramidal side effects (EPS (extrapyramidal syndrome) -- drug-induced parkinsonism, akathisia, acute dystonia); its low H1 affinity predicts minimal sedation; its low muscarinic affinity predicts minimal anticholinergic effects; and its moderate alpha1 affinity predicts orthostatic hypotension; this receptor-to-side-effect mapping is a core pharmacological tool for understanding and predicting antipsychotic tolerability
D) Haloperidol's receptor binding profile predicts its antipsychotic efficacy but adverse effects arise from pharmacokinetic accumulation in brain tissue rather than from the drug's affinity for non-dopaminergic receptors
E) The adverse effect profile of haloperidol cannot be predicted from receptor binding studies because in vivo receptor occupancy differs substantially from in vitro affinity measurements, making binding tables clinically irrelevant
ANSWER: C
Rationale:
Receptor binding affinity tables are one of the most pharmacologically useful tools for predicting and comparing antipsychotic tolerability profiles. The principle is straightforward: a drug will produce clinical effects corresponding to the receptors it occupies at therapeutic plasma concentrations, and the magnitude and character of each side effect reflects the receptor type blocked and the pathway involved. For haloperidol, the receptor binding-to-side-effect mapping demonstrates this principle clearly. High D2 affinity: occupancy of D2 receptors in the nigrostriatal pathway produces drug-induced parkinsonism, akathisia (motor restlessness), and acute dystonias; occupancy in the tuberoinfundibular pathway elevates prolactin (causing galactorrhea, menstrual irregularities). Low H1 affinity: haloperidol produces minimal sedation and minimal weight gain compared to agents with high H1 affinity such as clozapine, quetiapine, and olanzapine. Low muscarinic affinity: haloperidol produces minimal dry mouth, constipation, and urinary retention compared to low-potency antipsychotics such as chlorpromazine or thioridazine with higher muscarinic affinity. Moderate alpha1 affinity: haloperidol produces some orthostatic hypotension, though less than clozapine or chlorpromazine with their high alpha1 affinity. This receptor-based prediction of tolerability is the pharmacological foundation for individualizing antipsychotic selection -- matching the patient's specific comorbidities and sensitivities to the receptor binding profile of the chosen agent.
Option A: Option A is incorrect -- haloperidol's adverse effects are pharmacodynamically predictable from its receptor binding; they are not primarily idiosyncratic metabolite-mediated reactions.
Option B: Option B is incorrect -- sedation (H1), orthostatic hypotension (alpha1), and weight gain (H1) are not consequences of D2 blockade; they arise from other receptor interactions.
Option D: Option D is incorrect -- in vivo receptor occupancy at therapeutic concentrations is well-predicted from in vitro affinity data with appropriate PK (pharmacokinetic) corrections; binding tables are clinically relevant and form the basis of receptor-based pharmacology.
Option E: Option E is incorrect -- while in vivo occupancy and in vitro affinity differ quantitatively, the qualitative receptor binding profile reliably predicts the character of adverse effects.
3. A 76-year-old woman with moderate Alzheimer's disease and a prior hip fracture is prescribed diphenhydramine 50 mg at bedtime for insomnia. Her geriatrician objects strongly. Which of the following best explains the pharmacodynamic basis for this concern?
A) Diphenhydramine blocks histamine H1 receptors (causing sedation and CNS depression) and muscarinic receptors (causing cognitive impairment, confusion, and delirium); in a patient with Alzheimer's disease, whose cholinergic neurons are already severely depleted, additional muscarinic blockade produces additive anticholinergic burden that worsens cognitive function and increases delirium risk; the sedation from H1 blockade impairs balance and coordination, and together with the anticholinergic-induced confusion, dramatically increases fall risk in a patient with a prior hip fracture -- the combination of polypharmacy anticholinergic burden and underlying neurodegeneration makes diphenhydramine one of the most dangerous medications for this population
B) Diphenhydramine is problematic solely because of pharmacokinetic changes in the elderly -- reduced renal clearance prolongs its half-life to over 72 hours, producing drug accumulation and toxicity at standard doses
C) Diphenhydramine is problematic in this patient specifically because it is a potent CYP3A4 inhibitor that increases plasma concentrations of acetylcholinesterase inhibitors (donepezil, rivastigmine) that the patient is likely taking for Alzheimer's disease, producing cholinergic toxicity through a pharmacokinetic drug interaction
D) Diphenhydramine crosses the blood-brain barrier more readily in elderly patients due to age-related changes in P-glycoprotein expression at the blood-brain barrier, achieving higher CNS concentrations than in younger patients at the same dose
E) Diphenhydramine is problematic because elderly patients with Alzheimer's disease have upregulated H1 receptors in the hippocampus due to neurodegeneration, making them pharmacodynamically more sensitive to histamine blockade than younger patients with intact receptor density
ANSWER: A
Rationale:
Diphenhydramine's dangers in elderly patients with Alzheimer's disease are a direct consequence of its receptor binding profile interacting with the neurobiological substrate of the disease. Diphenhydramine is a first-generation antihistamine with high H1 receptor affinity (producing sedation) and high muscarinic receptor affinity (producing anticholinergic effects). Alzheimer's disease is characterized by progressive degeneration of cholinergic neurons in the nucleus basalis of Meynert and their projections to the hippocampus and cortex -- the cholinergic deficit is a central pathological feature and the rationale for acetylcholinesterase inhibitor therapy (donepezil, rivastigmine, galantamine). When a drug with high muscarinic receptor antagonist activity (diphenhydramine) is given to a patient whose brain is already severely cholinergically depleted, the drug's anticholinergic effects are superimposed on an already-compromised cholinergic system. The clinical consequence is acute-on-chronic worsening of cholinergic function: delirium, worsening confusion, visual hallucinations, urinary retention, and constipation. The H1 sedation adds impaired balance and psychomotor slowing to this picture. In a patient with a prior hip fracture, sedation plus delirium creates a very high fall-and-fracture risk. The Beers Criteria (American Geriatrics Society) explicitly lists diphenhydramine and all first-generation antihistamines as potentially inappropriate medications in older adults for precisely these pharmacodynamic reasons.
Option B: Option B is incorrect -- while elderly patients do have reduced renal clearance and longer half-lives for many drugs, diphenhydramine's primary concern in this patient is its pharmacodynamic receptor binding profile (H1 + muscarinic blockade), not a 72-hour half-life from renal accumulation.
Option C: Option C is incorrect -- diphenhydramine is not a potent CYP3A4 inhibitor; it does not produce clinically significant increases in acetylcholinesterase inhibitor concentrations through pharmacokinetic interaction.
Option D: Option D is incorrect -- while age-related changes in P-glycoprotein do affect CNS drug penetration to some degree, this is not the primary pharmacodynamic concern; the issue is the drug's receptor binding once it enters the CNS.
Option E: Option E is incorrect -- H1 receptor upregulation in Alzheimer's hippocampus is not the established explanation for diphenhydramine sensitivity; the primary concern is muscarinic blockade in an already cholinergically deficient brain.
4. A pharmaceutical company claims their new COX-2 (cyclooxygenase-2) selective anti-inflammatory drug achieves complete COX-2 inhibition with zero COX-1 activity, guaranteeing both GI (gastrointestinal) safety and cardiovascular safety. Which of the following best evaluates this claim?
A) The claim is correct -- complete COX-2 selectivity guarantees both GI safety (by preserving gastric COX-1-mediated prostaglandin production) and cardiovascular safety (since COX-2 has no role in cardiac or vascular prostaglandin balance)
B) The claim is incorrect for both endpoints -- complete COX-2 selectivity provides no GI protection because gastric mucosal integrity depends on COX-2, not COX-1, and cardiovascular risk remains from a different mechanism
C) The claim is irrelevant because COX-2 selectivity does not determine either GI or cardiovascular safety -- both adverse effects arise from non-COX pharmacological actions of NSAIDs (non-steroidal anti-inflammatory drugs) unrelated to prostaglandin synthesis
D) The claim is partially correct for GI safety but incorrect for cardiovascular safety -- complete COX-2 selectivity does preserve gastric COX-1 activity and reduces GI side effects by maintaining gastric mucosal prostaglandin E2 (PGE2) and prostacyclin PGI2 (prostacyclin) production from COX-1; however, it simultaneously reduces endothelial PGI2 production (which depends substantially on COX-2 in vascular endothelium) without reducing platelet thromboxane A2 (TXA2) production (which depends on COX-1 in platelets); this imbalance shifts the prostanoid milieu toward vasoconstriction and platelet aggregation, increasing thrombotic cardiovascular risk
E) The claim is correct that perfect selectivity guarantees GI safety, and the cardiovascular risk depends on the dose used rather than the selectivity ratio -- at low doses even COX-2 selective agents are cardiovascularly safe
ANSWER: D
Rationale:
This question directly applies the mechanistic pharmacodynamic understanding of COX isoforms to evaluate a drug development claim. The claim's GI safety component is correct: gastric mucosal integrity depends on prostaglandins (predominantly PGE2 and PGI2) produced by COX-1 in gastric mucosal cells and submucosal vasculature -- these prostaglandins stimulate mucus and bicarbonate secretion, maintain mucosal blood flow, and reduce acid secretion. Non-selective NSAIDs inhibit gastric COX-1 and reduce these protective prostaglandins, producing erosions, ulcers, and GI bleeding. A perfectly selective COX-2 inhibitor leaves gastric COX-1 intact and preserves gastric mucosal protection -- the GI safety claim is pharmacodynamically valid. The cardiovascular safety claim is incorrect for the reason that produced the rofecoxib (Vioxx) disaster: vascular endothelial cells express COX-2 constitutively, producing PGI2 (prostacyclin) -- a potent vasodilator and inhibitor of platelet aggregation. Platelets express only COX-1, producing TXA2 -- a potent vasoconstrictor and activator of platelet aggregation. Under normal physiological conditions, endothelial PGI2 and platelet TXA2 are in balance, maintaining vascular homeostasis. A COX-2 selective inhibitor reduces PGI2 production from endothelial COX-2 without reducing TXA2 production from platelet COX-1, tilting the balance toward thrombosis and vasoconstriction. The greater the COX-2 selectivity, the more pronounced this imbalance -- meaning perfect COX-2 selectivity would produce the maximum possible cardiovascular risk from this mechanism.
Option A: Option A is incorrect -- cardiovascular risk increases with COX-2 selectivity through the PGI2/TXA2 imbalance mechanism.
Option B: Option B is incorrect -- gastric mucosal protection depends on COX-1, and COX-2 selectivity does preserve GI safety; the GI component of the claim is correct.
Option C: Option C is incorrect -- both GI and cardiovascular adverse effects of NSAIDs are primarily prostaglandin-mediated through COX isoform pharmacology.
Option E: Option E is incorrect -- the cardiovascular risk is mechanism-based (PGI2/TXA2 imbalance) and correlates with the degree of COX-2 selectivity, not primarily with dose; even low doses of highly selective COX-2 inhibitors produce the prostanoid imbalance.
5. The therapeutic index (TI = TD50 (median toxic dose)/ED50 (median effective dose)) is a population statistic. A patient's individual effective therapeutic index may be substantially narrower than the population TI. Which of the following correctly identifies the three mechanisms by which an individual patient's effective therapeutic index can be compressed compared to the population value?
A) The individual TI is compressed only by pharmacokinetic factors -- altered absorption, distribution, metabolism, and excretion produce higher or lower plasma concentrations than expected, and these concentration deviations narrow the window between effective and toxic drug levels
B) Three mechanisms: (1) Pharmacokinetic variability -- the same dose produces different plasma concentrations across patients due to differences in absorption, distribution, metabolism (CYP polymorphisms, age, organ function), and excretion; a patient who achieves higher concentrations than average is effectively operating at the toxic end of the curve; (2) Pharmacodynamic sensitivity -- the same plasma concentration produces different effects across patients due to receptor density differences, downstream signaling efficiency, or disease-state changes in receptor sensitivity; (3) Drug interactions -- concurrent medications can shift both the effective concentration (through PK (pharmacokinetic) interactions) and the response curve (through PD (pharmacodynamic) interactions), compressing the window from both sides simultaneously
C) Three mechanisms: (1) Age -- elderly patients have narrower TI for all drugs due to reduced organ reserve; (2) Sex -- female patients metabolize most drugs more slowly, increasing toxicity risk; (3) Race -- pharmacogenomic differences in CYP enzymes reduce TI in certain populations; these three demographic factors fully account for individual TI compression
D) The individual TI cannot be compressed in an individual patient -- TI is a fixed pharmacological property of the drug determined by its molecular structure and binding kinetics; individual variation affects the dose required to achieve a given plasma concentration but does not change the fundamental TI of the compound
E) Individual TI compression occurs only through receptor upregulation and downregulation -- chronic drug exposure changes receptor density, shifting the ED50 upward (tolerance) and the TD50 downward (sensitization to toxicity), compressing the TI from both ends through receptor regulatory mechanisms
ANSWER: B
Rationale:
The population TI (TD50/ED50) describes the average ratio between the dose toxic in 50% of a population and the dose effective in 50% -- but individual patients can have a much narrower window between their personal effective dose and their personal toxic dose, for three fundamental reasons. First, pharmacokinetic variability: the same mg/kg dose produces a range of plasma concentrations across patients because of differences in gastrointestinal absorption (food effects, GI disease, formulation), distribution (body composition, plasma protein binding, tissue perfusion), metabolism (CYP enzyme polymorphisms -- CYP2C9 poor metabolizers on warfarin; CYP2D6 ultra-rapid metabolizers on codeine; age-related reductions in hepatic blood flow and CYP activity; drug interactions), and excretion (renal function, renal transporter polymorphisms). A patient who achieves plasma concentrations two-fold higher than the population average is functionally exposed to twice the dose. Second, pharmacodynamic sensitivity: the same plasma concentration produces different magnitudes of response in different patients due to receptor density (upregulated or downregulated receptors from disease or prior drug exposure), receptor coupling efficiency (G protein levels, second messenger signaling capacity), and downstream target sensitivity (e.g., increased bleeding sensitivity to warfarin in a patient with underlying coagulopathy). Third, drug interactions: concurrent medications can simultaneously shift effective concentrations (PK interactions through CYP inhibition/induction or transporter effects) and shift the response curve (PD interactions through additive or synergistic toxicity at the same concentration). A patient on warfarin started on fluconazole experiences both CYP2C9 inhibition (raising warfarin levels) and potentially additive bleeding risk -- both mechanisms compress the TI from both ends simultaneously. Options A and E each describe only one of the three mechanisms.
Option C: Option C incorrectly reduces individual TI compression to demographic factors, ignoring the pharmacokinetic and pharmacodynamic mechanisms that apply within demographic groups.
Option D: Option D is incorrect -- TI is a population-level descriptor and does not represent a fixed property of an individual's drug response; individual responses vary substantially.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.